@article{3072783,
    title = "A retrospective dosimetric comparison of TG43 and a commercially available MBDCA for an APBI brachytherapy patient cohort",
    author = "Zourari, K. and Major, T. and Herein, A. and Peppa, V. and Polgár, C. and Papagiannis, P.",
    journal = "PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS",
    year = "2015",
    volume = "31",
    number = "7",
    pages = "669-676",
    publisher = "Associazione Italiana di Fisica Medica",
    doi = "10.1016/j.ejmp.2015.05.010",
    keywords = "accelerated partial breast irradiation;  accuracy;  algorithm;  Article;  brachytherapy;  breast;  calculation;  clinical article;  cohort analysis;  controlled study;  dose calculation;  dose volume histogram;  dosimetry;  heart;  histogram;  human;  human tissue;  intermethod comparison;  lung;  model based dose calculation algorithm;  physical parameters;  planning target volyme;  radiation dose distribution;  retrospective study;  rib;  risk assessment;  risk factor;  skin;  TG186 dose calculation;  TG43 dose calculation;  treatment planning;  adverse effects;  brachytherapy;  comparative study;  organs at risk;  procedures;  radiation response;  radiometry;  radiotherapy planning system, Algorithms;  Brachytherapy;  Cohort Studies;  Humans;  Organs at Risk;  Radiometry;  Radiotherapy Planning, Computer-Assisted;  Retrospective Studies",
    abstract = "Purpose: To compare dosimetry using a contemporary model based dose calculation algorithm (MBDCA) following TG186 recommendations, and the conventional TG43 method in an 192Ir high dose rate (HDR) accelerated partial breast irradiation (APBI) patient cohort. Methods: Data of 38 APBI patients were studied. Dosimetry for the treatment plans was performed using both the TG43 and TG186 dose calculation methods of the Oncentra Brachy v4.4 treatment planning system (TPS). Analysis included indices of clinical interest for the planning target volume (PTV coverage, dose homogeneity, conformity) as well as dose volume histograms (DVH) for the breast, lung, heart, rib and skin. Significance testing of observed differences between TG43 and TG186 results was carried out and the effect of target location to these differences was studied. Results: Statistically significant differences were observed in the values of clinically relevant DVH parameters for the PTV and the organs at risk (OAR), except for the heart. Differences for the PTV are relatively small (<1% for coverage, on the order of 2% for homogeneity and conformity) with a slight TG43 overestimation except for the dose homogeneity. Percentage differences are larger for the rib and lung (on the order of 4% for Dmax and 5% for V10Gy, respectively) and maximum for the skin (on the order of 6% for D10cc), with a correlation of the observed differences with target location. Conclusion: While the MBDCA option of the TPS appears to improve dosimetric accuracy, differences from TG43 do not appear to warrant dose prescription changes or treatment protocol amendment. © 2015 Associazione Italiana di Fisica Medica."
}